Skip to content

TG Therapeutics TGTX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Biogen logo
BiogenBIIB
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
Arrowhead Research logo
Arrowhead ResearchARWR
Roivant Sciences logo
Roivant SciencesROIV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$204.9M+69.6%
Gross profit$171.4M+62.8%
Operating income$34.8M+304%
Net income$19.8M+291%
EPS (diluted)$0.12+300%

Balance sheet

See full
Cash & equivalents$442.2M+235%
Total debt$753.6M+197%
Total equity$583.1M+146%
Total assets$1.5B+133%

Cash flow

See full
Operating cash flow-$17.9M+37.7%
CapEx$51.0K+104%
Free cash flow-$17.9M+37.6%

Valuation

See full
Market cap$8.15B-14.3%
Enterprise value$8.46B-11.1%
P/E17.6×-225×
P/S11.6×-13.0×

Profitability

See full
Gross margin83.1%-4.4pp
Operating margin21.3%+5.9pp
Net margin66%+55.8pp
FCF margin-6,328.4%+4,773pp

Returns & leverage

See full
Return on equity112.6%+92.9pp
Debt / equity1.3×+0.2×
Current ratio5.8×+1.8×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about TG Therapeutics's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TG Therapeutics's software and technology licenses, net?
TG Therapeutics (TGTX) reported software and technology licenses, net of $2.02M in Q1 2026.
How has TG Therapeutics's software and technology licenses, net changed year-over-year?
TG Therapeutics's software and technology licenses, net decreased by 1.3% year-over-year, from $2.04M to $2.02M.
What is the long-term trend for TG Therapeutics's software and technology licenses, net?
Over 2 years (2023 to 2025), TG Therapeutics's software and technology licenses, net has grown at a -5.9% compound annual growth rate (CAGR), from $2.31M to $2.04M.